

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>glycopyrronium</b>
Brand Name	Seebri <sup>®</sup>
Dosage Form(s)	50 µg capsule for inhalation
Manufacturer	Novartis Pharmaceuticals Canada Inc.
<b>Submission Review</b>	<b>New Submission</b>
Use Reviewed	Glycopyrronium (Seebri <sup>®</sup> ) is reviewed for the treatment of chronic obstructive pulmonary disease (COPD)
Common Drug Review (CDR)	CDR recommended glycopyrronium be listed with criteria: <a href="http://www.cadth.ca/media/cdr/complete/cdr_complete_Seebri-May-17-13.pdf">http://www.cadth.ca/media/cdr/complete/cdr_complete_Seebri-May-17-13.pdf</a>
Drug Benefit Council (DBC)	DBC met on July 15, 2013. DBC considered the following: the final review completed by the Common Drug Review (CDR), which included clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC); Clinical Practice Review from one Specialist, Manufacturer comments; responses to Patient Input Questionnaires from one patient and one patient group; and a Budget Impact Analysis.
<b>Drug Coverage Decision</b>	<b>Limited Coverage benefit with criteria</b> <a href="http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/glycopyrronium.html">http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/glycopyrronium.html</a>
Date	September 19, 2013
Reason(s)	<b>Drug coverage decision is consistent with the DBC recommendation.</b> <ul style="list-style-type: none"> <li>• Glycopyrronium was similar to tiotropium with respect to efficacy and safety.</li> <li>• Based on economic considerations and the submitted product price, the drug was cost effective.</li> </ul>
Other Information	None

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit  
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit  
[www.health.gov.bc.ca/pharmacare](http://www.health.gov.bc.ca/pharmacare).

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.